Top Ten most popular articles on Pharmafile.com this week
It’s Friday, and there have been some big revelations for the pharma industry this week. Brexit, the ever-present hot topic has surged back to prominence and has taken centre stage in discussions between industry figures. There’s bad news for some of the industry’s big players between record fines and facility closures, and don’t miss Janssen’s VP of Process Sciences Mauricio Futran’s discussion on the benefits of continuous production.
Eli Lilly has successfully won its patent case against Teva Pharmaceuticals, with the case being decided at the US Court of Appeals. The case was regarded Lilly’s third biggest selling drug, Alimta, a treatment used in patients suffering from non-small cell lung cancer (NSCLC) and mesothelioma.
The BioIndustry Association (BIA) has accused new proposals put forward by the NICE of being “not fit for purpose” and potentially denying patients from accessing treatments for ultra-rare disease.
Next month, Johnson & Johnson will reveal the average price increases of its prescription drugs in a move to increase its transparency with patients.
Access Accelerated is a global initiative consisting of over 20 partners including Pfizer, GSK, J&J, Roche, Novartis and more to improve access to preventative measures against non-communicable disease.
The Scottish Medicines Consortium has decided not to recommend Janssen’s Darzalex (daratumumab) for routine use by NHS Scotland as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma.
Merck has completed a deal with Boston-based biotech firm Vertex Pharmaceuticals for the rights to four cancer programmes worth $230 million.
Japanese pharma firm Daiichi Sankyo has announced its intention to close its R&D centre in Gurgaon, India, a step in its global restructuring programme.
Mauricio Futran, vice president, Process Sciences, Janssen Supply Chain, discusses, in the latest issue of Pharmafile, Janssen’s move into continuous production and the benefits attained through the move.
Shire is accused of bribing clinicians and physicians by using kickbacks to encourage the use of Dermagraft, a diabetic foot ulcer treatment.
Theresa May has finally announced the first inklings of the government’s Brexit plan in a speech on Tuesday; BIA CEO Steve Bates gives his thoughts on the matter.
As the year winds to a close, excitement is rising around the efficacy and availability …
The top ten news stories this week focus on herd immunity, as the Director of …